Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elobixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 9/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | CTSD | P07339 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elobixibat SCHEMBL29351648 | 1.00 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| Elobixibat SCHEMBL5940599 | 1.00 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| Elobixibat SCHEMBL5386837 | 1.00 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| Elobixibat SCHEMBL29974592 | 0.99 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| SCHEMBL14559659 | 0.98 | NR1H4 (0.57) | NR1H4SLC10A2CTSD | |
| SCHEMBL5224917 | 0.98 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| SCHEMBL919390 | 0.98 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| SCHEMBL22484941 | 0.97 | NR1H4 (0.57) | NR1H4SLC10A2CTSD | |
| SCHEMBL22485252 | 0.97 | NR1H4 (0.56) | NR1H4SLC10A2CTSD | |
| SCHEMBL1183058 | 0.96 | NR1H4 (0.65) | NR1H4SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724071-A1 | NOVEL USE OF AN ILEAL BILE ACID TRANSPORTER INHIBITOR FOR THE TREATMENT OF PRURITUS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2026-04-15 | — | — | EP | claimed |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| EP-4629997-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | Albireo AB (SE) | 2025-10-15 | — | — | EP | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20250188473-A1 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | claimed |
| EP-4511038-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | Albireo AB (SE) | 2025-02-26 | — | — | EP | claimed |
| WO-2024251739-A1 | NOVEL USE OF AN ILEAL BILE ACID TRANSPORTER INHIBITOR FOR THE TREATMENT OF PRURITUS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2024-12-12 | — | — | WO | claimed |
| US-20240410902-A1 | USE OF SOLUBLE TREM2 AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) | REGION SYDDANMARK (DK) | 2024-12-12 | — | — | US | claimed |
| US-12123001-B2 | Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| EP-4422632-A1 | APICAL SODIUM-DEPENDENT TRANSPORTER INHIBITOR COMPOSITIONS | Mirum Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| US-20050215630-A1 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | claimed |
| US-20050171204-A1 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | claimed |
| JP-2005523255-A | — | — | 2005-08-04 | — | — | JP | claimed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | claimed |
| EP-1539120-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| US-20050124557-A1 | Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | US | claimed |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB R & D HEADQUARTERS - GLOBAL IINTELLECTUAL PROPERT (SE) | 2005-05-26 | — | — | US | claimed |
| EP-1478368-A1 | USE OF BENZOTHIAZEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT FOR REDUCING CHOLESTEROLOLEMIA | Astrazeneca AB (SE) | 2004-11-24 | — | — | EP | claimed |
| WO-2004006899-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | claimed |
| WO-2003061663-A1 | USE OF BENZOTHIAZEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT FOR REDUCING CHOLESTEROLOLEMIA | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | SLC10A2 175/4885NR1H4 94/4885CTSD 2273/4885 |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | COL1A1, COL2A1, FN1 | SLC10A2 254/4885NR1H4 250/4885CTSD 1030/4885 |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | PPARA, PPARD, PPARG | SLC10A2 434/4885NR1H4 33/4885CTSD 3213/4885 |
| US-20050171204-A1 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | PPARA, PPARD, PPARG | SLC10A2 209/4885NR1H4 46/4885CTSD 3453/4885 |
| US-20050215630-A1 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | PPARA, PPARG, PPARD | SLC10A2 557/4885NR1H4 41/4885CTSD 3115/4885 |
| US-20050124557-A1 | Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia | SLC10A2, SLC10A1, NR1H4 | SLC10A2 1/4885NR1H4 3/4885CTSD 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.